AlJazira Capital Sets Jamjoom Pharma's Target Price and Rating
Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a Q3 2025 net income of SAR 106.7 million, falling short of AlJazira Capital and market forecasts.
- Net income: SAR 106.7 million
- Period: Q3 2025
Meanwhile, Argaam Investment Company has updated its Privacy Policy for its services and digital platforms.
Argaam uses cookies to personalize content, provide social media features, and analyze traffic, which may be shared with third parties.
By using this website, you consent to Argaam's cookies.
Author's summary: AlJazira Capital updates Jamjoom Pharma's target price.
More News
- Cedar Key community bands together, hoping to survive hurricane season untouched - The Independent Florida Alligator
- Greyhound racing industry defends sport as Wales weighs ban
- Women and Quebec sovereignty: The missing half of the Yes vote
- FTSE Mixed as UK Lags Global Rally - Investomania
- London midday: FTSE nudges up amid trade deal hopes; HSBC falls
- Review: Bruce Springsteen biopic delivers authenticity and artistry - Washington Square News
- Two US Navy Aircraft and a Helicopter Crash in South China Sea, All Crew Rescued
- Saudi insurtech Najeeb.ai closes pre-seed round
- RWC 2027 Final Qualification Tournament Team Guide: Brazil
- Spanish shipbuilder defends himself after Uruguay cancels €82 million OPV contract